← All trials
NCT03940378
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2019
- Primary completion
- Feb 1, 2023
- Completion date
- Feb 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhengzhou UniversityLead sponsor
- Zhengzhou UniversityOverall official - principal investigator
- Zhengzhou UniversityReponsible party - principal investigator
- Anyang Regional HospitalCollaborator
- Xinjiang Medical UniversityCollaborator
- Nanyang Central HospitalCollaborator
- Luoyang Central HospitalCollaborator
- Sanmenxia Central HospitalCollaborator
- The Third People's Hospital of JiaozuoCollaborator
- pinmei Group General HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.